# A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder

> **NCT07478744** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Synendos Therapeutics AG** · enrollment: 24 (estimated)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** SYT-510
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07478744
- **Lead sponsor:** Synendos Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07478744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07478744, "A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07478744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*